Microwave ablation of the T1a small renal mass: expanding beyond 3cm.

Abstract

To compare the oncological and renal function outcomes for patients receiving microwave ablation (MWA) in tumors < 3 and 3-4cm. Retrospective analysis of a prospectively maintained database identified patients with < 3 or 3-4cm renal cancers undergoing MWA. Radiographic follow-up occurred at approximately 6months post-procedure and annually thereafter. Serum creatinine and estimated glomerular filtration rate (eGFR) were calculated before and 6-months post-MWA. Local recurrence-free survival (LRFS) was estimated using the Kaplan-Meier method. Tumor size was evaluated as a prognostic factor using Cox proportional-hazards regression. Predictors for change in eGFR and chronic kidney disease (CKD) stage were modeled using linear and ordinal logistic regression. A total of 126 patients fit the inclusion criteria. Overall recurrences were 2/62 (3.2%) and 6/64 (9.4%) for < 3 versus 3-4cm. Both recurrences in the < 3cm group were local, 4/6 in the 3-4cm group were local and 2/6 were metastatic without local progression. For < 3 versus 3-4cm, cumulative LRFS at 36months was 94.6% versus 91.4%. Tumor size was not a significant prognostic factor for LRFS. Renal function did not change significantly after MWA. Patient comorbidities and RENAL nephrometry score significantly affected change in CKD. With comparable oncological outcomes, complication rates, and renal function preservation, MWA is a promising management strategy for renal masses of 3-4cm in select patients. Our findings suggest that current AUA guidelines, which recommend thermal ablation for tumors < 3cm, may need review to include T1a tumors for MWA, regardless of size.